SKIN FIBROBLAST ACTIVITY IN PRETIBIAL MYXEDEMA AND THE EFFECT OF OCTREOTIDE (SANDOSTATIN(R)) IN-VITRO

Citation
Gc. Priestley et al., SKIN FIBROBLAST ACTIVITY IN PRETIBIAL MYXEDEMA AND THE EFFECT OF OCTREOTIDE (SANDOSTATIN(R)) IN-VITRO, British journal of dermatology, 131(1), 1994, pp. 52-56
Citations number
15
Categorie Soggetti
Dermatology & Venereal Diseases
ISSN journal
00070963
Volume
131
Issue
1
Year of publication
1994
Pages
52 - 56
Database
ISI
SICI code
0007-0963(1994)131:1<52:SFAIPM>2.0.ZU;2-0
Abstract
The accumulation of glycosaminoglycans in the skin in pretibial myxoed ema appears to be a response by local fibroblasts to a stimulating fac tor in the patient's serum, but the identity of the factor, its abilit y to stimulate skin fibroblasts as opposed to cultured thyroid cells, and the specificity of its effect to pretibial skin fibroblasts, are a ll controversial. We have studied fibroblasts cultured from the lesion al skin of two women with pretibial myxoedema, and compared their prol iferation and secretion of glycosaminoglycans with those of fibroblast s from the patients' forearms and from the forearm skin of two normal subjects. We found that in the presence of the patients' sera all six lines of fibroblasts secreted more glycosaminoglycans [205 +/- 21% (SD )] than with normal human sera (147 +/- 19%), or fetal calf serum (100 %). Fibroblast proliferation showed the same pattern of differences: p atients' sera 142 +/- 22%; normal human sera 116 +/- 9%, and fetal cal f serum 100%. These experiments confirm the presence of a serum factor in pretibial myxoedema which is capable of stimulating the activity o f skin fibroblasts in vitro, and show that its effects are not restric ted to fibroblasts from pretibial skin or to those grown from the skin of the patients. Proliferation of normal fibroblasts cultured in medi um supplemented with fetal calf serum was reduced by Sandostatin(R) (o ctreotide), but it failed to inhibit their secretion of glycosaminogly cans. In contrast, secretion of glycosaminoglycans by a patient's pret ibial skin fibroblasts was almost completely inhibited by 1 mM minoxid il. In the presence of patients' sera Sandostatin(R) (0.1-10 mu g/ml) reduced secretion of glycosaminoglycans by about 50%. Our data support the use of Sandostatin(R) in pretibial myxoedema, and suggest that it may suppress fibroblast glycosaminoglycan secretion within the skin v ia depletion of insulin-like growth factor or the blocking of its effe ct.